M E Wacker1, R A Jörres2, H Schulz3, J Heinrich3, S Karrasch4, A Karch5, A Koch5, A Peters6, R Leidl7, C Vogelmeier8, R Holle9. 1. Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany. Electronic address: margarethe.wacker@helmholtz-muenchen.de. 2. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336 Munich, Germany. 3. Institute of Epidemiology I, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany. 4. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336 Munich, Germany; Institute of Epidemiology I, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany; Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Orleansstr. 47, 81667 Munich, Germany. 5. Institute for Biostatistics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 6. Institute of Epidemiology II, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany. 7. Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany; Institute of Health Economics and Health Care Management, Munich Center of Health Sciences, Ludwig-Maximilians-Universität München, Ludwigstr. 28/RG, 80539 Munich, Germany. 8. Department of Respiratory Medicine, University of Marburg, University Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Baldingerstraße, 35043 Marburg, Germany. 9. Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH) - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany.
Abstract
BACKGROUND: Reliable up-to-date estimates regarding the economic impact of chronic obstructive pulmonary disease (COPD) are lacking. This study investigates COPD excess healthcare utilization, work absenteeism, and resulting costs within the German COPD cohort COSYCONET. METHODS: Data from 2139 COPD patients in GOLD grade 1-4 from COSYCONET were compared with 1537 lung-healthy control subjects from the population-based KORA platform. Multiple generalized linear models analyzed the association of COPD grades with healthcare utilization, work absence, and costs from a societal perspective while adjusting for sex, age, education, smoking status, body mass index (BMI), and several comorbidities. RESULTS: COPD was significantly associated with excess healthcare utilization, work absence, and premature retirement. Adjusted annual excess cost of COPD in 2012 for GOLD grade 1-4 amounted to €2595 [1770-3678], €3475 [2966-4102], €5955 [5191-6843], and €8924 [7190-10,853] for direct costs, and €8621 [4104-13,857], €9871 [7692-12,777], €16,550 [13,743-20,457], and €27,658 [22,275-35,777] for indirect costs respectively. Comorbidities contributed to the primary effect of COPD on direct costs only. An additional history of cancer or stroke had the largest effect on direct costs, but the effects were smaller than those of COPD grade 3/4. CONCLUSIONS: COPD is associated with substantially higher costs than previously reported.
BACKGROUND: Reliable up-to-date estimates regarding the economic impact of chronic obstructive pulmonary disease (COPD) are lacking. This study investigates COPD excess healthcare utilization, work absenteeism, and resulting costs within the German COPD cohort COSYCONET. METHODS: Data from 2139 COPDpatients in GOLD grade 1-4 from COSYCONET were compared with 1537 lung-healthy control subjects from the population-based KORA platform. Multiple generalized linear models analyzed the association of COPD grades with healthcare utilization, work absence, and costs from a societal perspective while adjusting for sex, age, education, smoking status, body mass index (BMI), and several comorbidities. RESULTS:COPD was significantly associated with excess healthcare utilization, work absence, and premature retirement. Adjusted annual excess cost of COPD in 2012 for GOLD grade 1-4 amounted to €2595 [1770-3678], €3475 [2966-4102], €5955 [5191-6843], and €8924 [7190-10,853] for direct costs, and €8621 [4104-13,857], €9871 [7692-12,777], €16,550 [13,743-20,457], and €27,658 [22,275-35,777] for indirect costs respectively. Comorbidities contributed to the primary effect of COPD on direct costs only. An additional history of cancer or stroke had the largest effect on direct costs, but the effects were smaller than those of COPD grade 3/4. CONCLUSIONS:COPD is associated with substantially higher costs than previously reported.
Authors: Peter Ascanius Jacobsen; Kristian Kragholm; Christian Torp-Pedersen; Ulla Møller Weinreich Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-10-11
Authors: Jana Graf; Rudolf A Jörres; Tanja Lucke; Dennis Nowak; Claus F Vogelmeier; Joachim H Ficker Journal: Dtsch Arztebl Int Date: 2018-09-14 Impact factor: 5.594
Authors: Su-Jong Kim-Dorner; Torben Schmidt; Alexander Kuhlmann; Johann-Matthias Graf von der Schulenburg; Tobias Welte; Heidrun Lingner Journal: NPJ Prim Care Respir Med Date: 2022-05-02 Impact factor: 2.871
Authors: Tanja Lucke; Ronald Herrera; Margarethe Wacker; Rolf Holle; Frank Biertz; Dennis Nowak; Rudolf M Huber; Sandra Söhler; Claus Vogelmeier; Joachim H Ficker; Harald Mückter; Rudolf A Jörres Journal: PLoS One Date: 2016-10-28 Impact factor: 3.240
Authors: Maria Montes de Oca; Carlos Aguirre; Maria Victorina Lopez Varela; Maria E Laucho-Contreras; Alejandro Casas; Filip Surmont Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-12-07
Authors: Florian M Karl; Rolf Holle; Robert Bals; Timm Greulich; Rudolf A Jörres; Annika Karch; Armin Koch; Stefan Karrasch; Reiner Leidl; Holger Schulz; Claus Vogelmeier; Margarethe E Wacker Journal: Respir Res Date: 2017-04-17